Phase 3 N=139 Levodopa for the Treatment of Residual Amblyopia
Amblyopia
Primary: Distribution of Amblyopic Eye Visual Acuity Change From Baseline — 0; 0; 2; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=551 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks. — -207.32; -113.59 mL/year — p=0.0002
Phase 3 N=441 NVA237 Versus Placebo 12-week Efficacy Study
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline of Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing — 0.125; -0.014 liters*hr
Phase 3 N=176 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
Breast Cancer · Dermatologic Complications · Radiation Toxicity
Primary: Mean Maximum Grade of Radiation Dermatitis by Treatment Arm. — 1.2; 1.3 Grade — p=0.18
Phase 3 N=69 Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
Cystic Fibrosis
Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 — 2.5724; 0.4611 percent predicted of FEV1 — p=0.1979
Phase 3 N=234 Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
Seasonal Influenza · Cough · Sore Throat
Primary: Change From Baseline in Influenza Virus Titer (48 Hours) — -1.66; -1.47 log10 TCID50/mL
Phase 3 N=104 Citicoline Treatment of Methamphetamine Dependence
Methamphetamine Dependence
Primary: Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo — 0.3025; 0.3850 total amount consumed in grams
Phase 3 N=889 A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008) — 89.5; 79.9 percentage of…
Phase 3 N=149 An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)
Fibromyalgia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 138 participants
Phase 3 N=300 BOTOX® in the Treatment of Crow's Feet Lines in Japan
Lateral Canthus Rhytides · Crow's Feet Lines
Primary: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle…
Phase 3 N=101 BOTOX® in the Treatment of Upper Facial Lines in Japan
Upper Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle…
Phase 3 N=464 Bimatoprost in the Treatment of Eyelash Hypotrichosis
Idiopathic Eyelash Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA) — 82.4…
Phase 3 N=846 Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
Metabolism and Nutrition Disorder · Obesity
Primary: Change (%) From Baseline in Body Weight (Fasting) — -5.9; -4.6; -2.0 percent change — p=<0.0001
Phase 3 N=359 Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Metabolism and Nutrition Disorder · Obesity · Obstructive Sleep Apnoea
Primary: Change From Baseline in Apnoea-hypopnoea Index (AHI) — -12.22; -6.08 events/hour — p=0.015
Phase 3 N=547 A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures
Epilepsy · Partial Onset Seizures
Primary: Change in Partial-Onset Seizure Frequency Per 28 Days From Baseline to the Maintenance Period — -1.22; -3.33; -4.50 Seizures per 28 days — p=<0.001